This project will test whether activators of a novel estrogen receptor (GPER) can limit brain injury and functional deficits after stroke in mice. Part of the work will evaluate two drugs currently in clinical use for chronic conditions – tamoxifen and estradiol – as potential therapies for use in acute stroke. We will study the therapeutic time window of several drugs over up to a week after stroke, and identify key mechanisms underlying the protection by these GPER drugs.
Does A Novel Estrogen Receptor Worsen Stroke Outcome?
Funder
National Health and Medical Research Council
Funding Amount
$524,820.00
Summary
This project will test whether a target protein for estrogen, called GPER, which is found in high levels in the brain, worsens stroke outcome. We will identify the key signalling pathways related to GPER in the brain after stroke and we hope to identify a new type of drug that could be used to treat stroke patients. It is possible that our work could at least partly explain why hormone replacement therapy can increase the risk of worsened outcome after stroke in women.